GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Days Sales Outstanding

BioNexus Gene Lab (BioNexus Gene Lab) Days Sales Outstanding : 34.12 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is BioNexus Gene Lab Days Sales Outstanding?

BioNexus Gene Lab's average Accounts Receivable for the three months ended in Dec. 2023 was $0.85 Mil. BioNexus Gene Lab's Revenue for the three months ended in Dec. 2023 was $2.27 Mil. Hence, BioNexus Gene Lab's Days Sales Outstanding for the three months ended in Dec. 2023 was 34.12.

The historical rank and industry rank for BioNexus Gene Lab's Days Sales Outstanding or its related term are showing as below:

BGLC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.51   Med: 102.19   Max: 128.09
Current: 69.43

During the past 6 years, BioNexus Gene Lab's highest Days Sales Outstanding was 128.09. The lowest was 68.51. And the median was 102.19.

BGLC's Days Sales Outstanding is ranked worse than
55.54% of 1525 companies
in the Chemicals industry
Industry Median: 64.02 vs BGLC: 69.43

BioNexus Gene Lab's Days Sales Outstanding declined from Dec. 2022 (89.85) to Dec. 2023 (34.12).

BioNexus Gene Lab Days Sales Outstanding Historical Data

The historical data trend for BioNexus Gene Lab's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNexus Gene Lab Days Sales Outstanding Chart

BioNexus Gene Lab Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial - 128.09 100.43 103.95 68.51

BioNexus Gene Lab Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 89.85 103.59 83.98 55.31 34.12

Competitive Comparison of BioNexus Gene Lab's Days Sales Outstanding

For the Specialty Chemicals subindustry, BioNexus Gene Lab's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioNexus Gene Lab's Days Sales Outstanding Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where BioNexus Gene Lab's Days Sales Outstanding falls into.


BioNexus Gene Lab Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

BioNexus Gene Lab's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (2.868 + 0.8) / 2 ) / 9.771*365
=1.834 / 9.771*365
=68.51

BioNexus Gene Lab's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding (Q: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2023 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (0.9 + 0.8) / 2 ) / 2.273*365 / 4
=0.85 / 2.273*365 / 4
=34.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNexus Gene Lab  (NAS:BGLC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

BioNexus Gene Lab Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of BioNexus Gene Lab's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNexus Gene Lab (BioNexus Gene Lab) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BioNexus Gene Lab Corp (NAS:BGLC) » Definitions » Days Sales Outstanding
Comparable Companies
NMGX CNEY CBNT HYDI COWI AMRSQ SNES CRKN ETCK PVNNF LIN XPAR:AI APD SHW ECL SHSE:600309 XSWX:SIKA BOM:500820 DD XSWX:GIVN
Traded in Other Exchanges
N/A
Address
No. 8 Jalan Kerinchi, The Vertical Business Suite II, Unit 02, Level 10, Tower B, Avenue 3, Bangar South, Kuala Lumpur, SGR, MYS, 59200
Website
https://www.bionexusgenelab.com
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Executives
Chak Hua Yew director 1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yeat Min Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Teng Fook Fong director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chee Keong Yap director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Boon Teong Teoh director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Yee Meng Wong director, officer: President 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Wei Li Leong officer: Chief Financial Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Chai Ping Lin director 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Tai Tan Liong director, officer: Chief Operating Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200
Sook Keng Yeoh director, officer: Chief Executive Officer 10-2 TOWER B, VERTICAL BUSINESS SUITE, 8 JALAN KERINCHI, KUALA LUMPUR N8 59200